1. Home
  2. BEAM vs FFBC Comparison

BEAM vs FFBC Comparison

Compare BEAM & FFBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • FFBC
  • Stock Information
  • Founded
  • BEAM 2017
  • FFBC 1863
  • Country
  • BEAM United States
  • FFBC United States
  • Employees
  • BEAM N/A
  • FFBC N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • FFBC Major Banks
  • Sector
  • BEAM Health Care
  • FFBC Finance
  • Exchange
  • BEAM Nasdaq
  • FFBC Nasdaq
  • Market Cap
  • BEAM 2.3B
  • FFBC 2.3B
  • IPO Year
  • BEAM 2020
  • FFBC N/A
  • Fundamental
  • Price
  • BEAM $23.23
  • FFBC $23.66
  • Analyst Decision
  • BEAM Strong Buy
  • FFBC Buy
  • Analyst Count
  • BEAM 11
  • FFBC 7
  • Target Price
  • BEAM $49.40
  • FFBC $28.83
  • AVG Volume (30 Days)
  • BEAM 2.6M
  • FFBC 468.9K
  • Earning Date
  • BEAM 11-04-2025
  • FFBC 10-23-2025
  • Dividend Yield
  • BEAM N/A
  • FFBC 4.22%
  • EPS Growth
  • BEAM N/A
  • FFBC 16.38
  • EPS
  • BEAM N/A
  • FFBC 2.70
  • Revenue
  • BEAM $55,701,000.00
  • FFBC $815,886,000.00
  • Revenue This Year
  • BEAM N/A
  • FFBC $20.97
  • Revenue Next Year
  • BEAM $19.01
  • FFBC $20.70
  • P/E Ratio
  • BEAM N/A
  • FFBC $8.77
  • Revenue Growth
  • BEAM N/A
  • FFBC 7.05
  • 52 Week Low
  • BEAM $13.53
  • FFBC $21.10
  • 52 Week High
  • BEAM $35.25
  • FFBC $31.18
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 42.93
  • FFBC 41.42
  • Support Level
  • BEAM $26.90
  • FFBC $23.09
  • Resistance Level
  • BEAM $26.17
  • FFBC $24.06
  • Average True Range (ATR)
  • BEAM 1.84
  • FFBC 0.55
  • MACD
  • BEAM -0.68
  • FFBC 0.01
  • Stochastic Oscillator
  • BEAM 11.47
  • FFBC 36.21

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About FFBC First Financial Bancorp.

First Financial Bancorp is a mid-sized, regional bank holding company. It engages in the business of commercial banking and other banking and banking-related activities through its subsidiary. The range of banking services provided to individuals and businesses includes commercial lending, real estate lending and consumer financing. Real estate loans are loans secured by a mortgage lien on the real property of the borrower, which may either be residential property or commercial property. In addition, it offers deposit products that include interest-bearing and noninterest-bearing accounts, time deposits and cash management services for commercial customers. A full range of trust and wealth management services is also provided through First Financial's Wealth Management line of business.

Share on Social Networks: